1. Comparative efficacy of tyrosine kinase inhibitor treatments in the third-line setting, for chronic-phase chronic myelogenous leukemia after failure of second-generation tyrosine kinase inhibitors. Issue 1 (January 2015) Authors: Lipton, J.H.; Bryden, P.; Sidhu, M.K.; Huang, H.; McGarry, L.J.; Lustgarten, S.; Mealing, S.; Woods, B.; Whelan, J.; Hawkins, N. Journal: Leukemia research Issue: Volume 39:Issue 1(2015:Jan.) Page Start: 58 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Novel therapies in chronic lymphocytic leukaemia (CLL): quantifying the impact on patient relevant outcome measures. (February 2017) Authors: Singh, M.; Mealing, S.; Cote, S.; Baculea, S. Journal: European journal of cancer Issue: Volume 72(2017)Supplement 1 Page Start: S99 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Time trade-off study to establish utility decrements in individuals with a spinal cord injury who perform intermittent catheterization. (31st December 2023) Authors: Looby, A.; Davies, H.; Mealing, S.; Smith, A. B.; Avey, B.; Laezza, A.; Crossland, A.; Lane, E. F.; Ridler, M.; Cawson, M. Journal: Journal of medical economics Issue: Volume 26:Number 1(2023) Page Start: 430 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Unveiling the true costs and societal impacts of moderate‐to‐severe atopic dermatitis in Europe. (7th July 2022) Authors: Augustin, M.; Misery, L.; von Kobyletzki, L.; Armario‐Hita, J.C.; Mealing, S.; Redding, M. Journal: Journal of the European Academy of Dermatology and Venereology Issue: Volume 36:Number 7(2022)supplement 7 Page Start: 3 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗